The Zacks Analyst Blog Highlights: Arena Pharmaceuticals, Gilead Sciences, GlaxoSmithKline, Actelion and United Therapeutics

  The Zacks Analyst Blog Highlights: Arena Pharmaceuticals, Gilead Sciences,
              GlaxoSmithKline, Actelion and United Therapeutics

PR Newswire

CHICAGO, Oct. 16, 2012

CHICAGO, Oct. 16, 2012 /PRNewswire/ --Zacks.com announces the list of stocks
featured in the Analyst Blog. Every day the Zacks Equity Research analysts
discuss the latest news and events impacting stocks and the financial markets.
Stocks recently featured in the blog include Arena Pharmaceuticals, Inc.
(Nasdaq:ARNA), Gilead Sciences Inc. (Nasdaq:GILD), GlaxoSmithKline plc
(NYSE:GSK), Actelion Ltd. (OTC:ALIOF) and United Therapeutics Corporation
(Nasdaq:UTHR).

(Logo: http://photos.prnewswire.com/prnh/20101027/ZIRLOGO)

Get the most recent insight from Zacks Equity Research with the free Profit
from the Pros newsletter: http://at.zacks.com/?id=5513

Here are highlights from Monday's Analyst Blog:

Arena Pharma Initiates PAH Study

Arena Pharmaceuticals, Inc. (Nasdaq:ARNA) recently initiated a phase I
multiple dose study with APD811, which is being developed for the treatment of
pulmonary arterial hypertension (PAH).

Arena Pharma is expecting to enroll 30 healthy adult volunteers for this
randomized, double-blind and placebo-controlled dose titration trial. The
trial will study the safety, tolerability and pharmacokinetics of the
candidate.

We note that the PAH market already has players like Gilead Sciences Inc.
(Nasdaq:GILD), GlaxoSmithKline plc (NYSE:GSK), Actelion Ltd. (OTC:ALIOF) and
United Therapeutics Corporation (Nasdaq:UTHR).

Meanwhile, Arena Pharma achieved a major milestone in June this year when the
US Food and Drug Administration (FDA) approved Belviq as an adjunct to a
healthy diet (low on calories) and increased physical activity for chronic
weight management in obese (Body Mass Index, or BMI, ≥30) or overweight (BMI
≥27) adults suffering from at least one weight-related co-morbid condition.
The move marks the first FDA approval for a weight-loss drug in 13 years.

The safety and efficacy of Belviq when co-administered with other weight loss
products and the effect on cardiovascular morbidity and mortality are yet to
be established. Hence, the FDA recommended Belviq to be classified by the US
Drug Enforcement Administration (DEA) as a scheduled drug.

Belviq is currently under review in the EU and the company has filed a
marketing application in Switzerland. Arena Pharma and Eisai have a
partnership agreement for Belviq.

Our Recommendation

We currently have a Neutral recommendation on Arena Pharma. The stock carries
a Zacks #3 Rank (short-term Hold rating).

Want more from Zacks Equity Research? Subscribe to the free Profit from the
Pros newsletter: http://at.zacks.com/?id=5515.

About Zacks Equity Research

Zacks Equity Research provides the best of quantitative and qualitative
analysis to help investors know what stocks to buy and which to sell for the
long-term.

Continuous coverage is provided for a universe of 1,150 publicly traded
stocks. Our analysts are organized by industry which gives them keen insights
to developments that affect company profits and stock performance.
Recommendations and target prices are six-month time horizons.

Zacks "Profit from the Pros" e-mail newsletter provides highlights of the
latest analysis from Zacks Equity Research. Subscribe to this free newsletter
today: http://at.zacks.com/?id=5517

About Zacks

Zacks.com is a property of Zacks Investment Research, Inc., which was formed
in 1978 by Leon Zacks. As a PhD from MIT Len knew he could find patterns in
stock market data that would lead to superior investment results. Amongst his
many accomplishments was the formation of his proprietary stock picking
system; the Zacks Rank, which continues to outperform the market by nearly a 3
to 1 margin. The best way to unlock the profitable stock recommendations and
market insights of Zacks Investment Research is through our free daily email
newsletter; Profit from the Pros. In short, it's your steady flow of
Profitable ideas GUARANTEED to be worth your time! Register for your free
subscription to Profit from the Pros at http://at.zacks.com/?id=5518.

Visit http://www.zacks.com/performance for information about the performance
numbers displayed in this press release.

Follow us on Twitter: http://twitter.com/zacksresearch

Join us on Facebook:
http://www.facebook.com/home.php#/pages/Zacks-Investment-Research/57553657748?ref=ts

Disclaimer: Past performance does not guarantee future results. Investors
should always research companies and securities before making any investments.
Nothing herein should be construed as an offer or solicitation to buy or sell
any security.

Media Contact

Zacks Investment Research

800-767-3771 ext. 9339

support@zacks.com

http://www.zacks.com

SOURCE Zacks Investment Research, Inc.

Website: http://www.zacks.com